These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 19590489)

  • 1. Golimumab (simponi) for inflammatory arthritis.
    Med Lett Drugs Ther; 2009 Jul; 51(1316):55-6. PubMed ID: 19590489
    [No Abstract]   [Full Text] [Related]  

  • 2. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V; Plosker GL
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Voulgari PV
    Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab.
    Mazumdar S; Greenwald D
    MAbs; 2009; 1(5):422-31. PubMed ID: 20065639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.
    Chovel-Sella A; Karplus R; Sella T; Amital H
    Isr Med Assoc J; 2012 Jun; 14(6):390-4. PubMed ID: 22891404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of golimumab in the treatment of arthritis.
    Fleischmann R
    Expert Opin Biol Ther; 2010 Jul; 10(7):1131-43. PubMed ID: 20504106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In brief: new indications for secukinumab (Cosentyx).
    Med Lett Drugs Ther; 2016 Jun; 58(1496):76. PubMed ID: 27249098
    [No Abstract]   [Full Text] [Related]  

  • 9. Golimumab, the newest TNF-α blocker, comes of age.
    Papagoras C; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2015; 33(4):570-7. PubMed ID: 25602858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Zhou Y; Goldstein N; Braun J
    J Rheumatol; 2016 Dec; 43(12):2120-2130. PubMed ID: 27803138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics in Inflammatory and Immunomediated Arthritis.
    Luchetti MM; Benfaremo D; Gabrielli A
    Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Campas-Moya C
    Drugs Today (Barc); 2010 Jan; 46(1):13-22. PubMed ID: 20200692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review on golimumab in the treatment of psoriatic arthritis.
    Urdaneta M; Jethwa H; Sultan R; Abraham S
    Immunotherapy; 2017 Sep; 9(11):871-889. PubMed ID: 28838285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Are there any evidences for using the intra-articular TNF-α blockade in resistant arthritis?".
    Fiocco U; Punzi L
    Joint Bone Spine; 2011 Jul; 78(4):331-4. PubMed ID: 21353617
    [No Abstract]   [Full Text] [Related]  

  • 16. Golimumab and immunogenicity? 2010 and beyond.
    Zidi I; Bouaziz A; Ben Amor N
    Pharmazie; 2011 Apr; 66(4):233-43. PubMed ID: 21612149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
    Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
    Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-a-month injection approved to treat three types of arthritis.
    Thompson CA
    Am J Health Syst Pharm; 2009 Jun; 66(11):968. PubMed ID: 19451600
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
    Lozeron P; Denier C; Lacroix C; Adams D
    Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Leu JH; Adedokun OJ; Gargano C; Hsia EC; Xu Z; Shankar G
    Rheumatology (Oxford); 2019 Mar; 58(3):441-446. PubMed ID: 30412238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.